National database for rare skin cancers in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national cohort of patients with rare skin cancers, specifically Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinoma. It will collect comprehensive epidemiological, clinical, and socio-economic data from 37 French centers to better understand these conditions. The study will also identify new prognostic factors and evaluate the impact of various treatments on patient outcomes through a centralized database.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Exclusion Criteria:

* Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
* Patients refusal

Where it's running

• CHU Bocage
  Dijon, Dijon, France Recruiting
• CH Le Mans
  Le Mans, Le Mans, France Recruiting
• Centre hospitalier Lyon Sud
  Pierre-Bénite, Pierre-benite, France Recruiting
• CHU Amiens Picardie
  Amiens, France Recruiting
• CHU Angers
  Angers, France Recruiting
• CH Annecy Gennevois
  Annecy, France Recruiting

Study contacts

• Principal investigator: Laurent MORTIER, MD,PhD — University Hospital, Lille
• Study coordinator: Laurent MORTIER, MD,PhD
• Email: laurent.mortier@chru-lille.fr
• Phone: 03.20.44.41.93

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lifileucel (TIL) plus chemotherapy and IL-2 for advanced cutaneous squamous cell and Merkel cell carcinoma

  This trial will try lifileucel (tumor-infiltrating lymphocytes) combined with lymphodepleting chemotherapy and interleukin-2 in adults with unresectable or metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma who have previously received immunotherapy.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07288073

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Electrochemotherapy for unresectable visceral tumors including liver metastases

  This will try electrochemotherapy with bleomycin in adults who have unresectable primary or metastatic visceral tumors, such as liver metastases.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06753136

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.